AdvanSource Biomaterials enters multi-year supply agreement with global coated medical devices company

AdvanSource Biomaterials Corporation (OTC Markets OTCQB: ASNB), a leading developer of advanced polymer materials for a broad range of medical devices, today announced it has entered into a multi-year supply agreement with an international medical diagnostics device company engaged in the business of developing medical device coatings and developing, manufacturing and selling coated medical devices.

Khristine Carroll, AdvanSource's SVP of Commercial Operations, stated, "We are very pleased with this opportunity to expand our commercial relationship and partnership with this client through our hydrophilic materials product portfolio. This agreement further emphasizes the growing recognition and importance of offering specifically targeted materials to optimize end-product characteristics. We continue to aggressively market our technology and capabilities; and are optimistic and proud of the medical device industry's recognition and support of the benefits of our advanced biomaterials and services."

This new agreement, which is effective this calendar year, represents a new addition to AdvanSource's portfolio of multi-year supply agreements, providing for minimum annual purchases.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Majority of AI clinical trials report positive outcomes, yet concerns over generalizability persist